Qiagen stock weighs stronger Q3 margins against suspended outlook

QIAGEN reported stronger third-quarter profitability on Wednesday, November 4, while suspending its full-year outlook because of the pending transaction with EQT Private Equity. The QIAGEN investor relations release said sales and adjusted diluted earnings per share exceeded the company outlook.

Sales Growth Beats Company Outlook

QIAGEN generated third-quarter net sales of 548 million US dollars, up 3 percent from the same quarter a year earlier. Growth was also 3 percent at constant exchange rates, above the company outlook for approximately 1 to 2 percent constant-currency growth.

Consumables and related revenues increased 3 percent at constant exchange rates and represented 91 percent of sales. Instrument revenue rose 1 percent, while sales from QIAGEN's growth pillars increased 7 percent at constant exchange rates to 415 million US dollars. The rest of the portfolio declined 7 percent at constant exchange rates.

Adjusted Margin Moves Higher

Reported operating income rose to 132 million US dollars from 129 million US dollars in the year-earlier quarter. Adjusted operating income, which excludes specified charges and other items, increased 6 percent to 167 million US dollars.

The adjusted operating income margin reached 30.4 percent, compared with 29.6 percent a year earlier. QIAGEN attributed the improvement to sales growth, a larger contribution from higher-margin consumables and efficiency gains. The company also continued to invest in Parse Biosciences following its acquisition in late 2025.

Reported diluted earnings per share fell to 0.51 US dollars from 0.60 US dollars. Adjusted diluted earnings per share increased to 0.65 US dollars from 0.61 US dollars and exceeded the outlook of at least 0.62 US dollars at constant exchange rates. QIAGEN also reported operating cash flow of 447 million US dollars for the first nine months of 2026, compared with 466 million US dollars in the prior-year period.

EQT Transaction Limits the Outlook

QIAGEN said it will not provide financial guidance while the proposed transaction with EQT remains pending. The tender offer has not yet commenced, and the company continues to operate under its current management until completion. The transaction therefore leaves investors weighing the improved operating performance against the uncertainty surrounding the timetable and conditions for the takeover.

For investors, the adjusted figures offer the clearest view of current operating momentum, but they are non-GAAP measures and should not be treated as a replacement for reported earnings. The suspended outlook also removes a standard reference point for judging the next quarters, making updates on the transaction and underlying demand especially important.

Shares Trade During Tuesday Session

Qiagen stock traded at 45.14 euros on Lang & Schwarz at 11:40 CET on Tuesday, November 10, 2026.

The Dutch market backdrop remains relevant through the AEX market.

Further developments on the transaction, including the start of the tender offer and regulatory progress, are likely to remain the main external focus for the Qiagen stock news and analysis.